



## OpGen Announces Pricing of Public Offering of Common Stock

October 18, 2018

GAITHERSBURG, Md., Oct. 18, 2018 (GLOBE NEWSWIRE) -- **OpGen, Inc. (NASDAQ: OPGN)** today announced the pricing of an underwritten public offering of approximately 2.2 million shares of its common stock at a public offering price of \$1.45 per share. The company has also granted to the underwriters a 45-day option to acquire an additional 330,751 shares to cover overallocments in connection with the offering. The gross proceeds to OpGen from this offering, before deducting underwriting discounts and commissions and offering expenses payable by OpGen, are expected to be approximately \$3.2 million. The offering is expected to close on or about October 22, 2018, subject to customary closing conditions.

The Company intends to use the net proceeds of this offering for research and development, including funding the continued development and manufacturing of its Acuitas® AMR Gene Panel tests, including its Acuitas AMR Gene Panel u5.47 that was released for Research Use Only in February 2018 and its Acuitas Lighthouse® software, to support acquisitions of products and technologies, capital expenditures, working capital and other general corporate purposes.

Aegis Capital Corp. acted as the sole book-running manager for the offering.

The shares will be issued pursuant to a shelf registration statement previously filed with and subsequently declared effective by the Securities and Exchange Commission (SEC). A final prospectus supplement and accompanying prospectus will be filed with the SEC. A copy of the final prospectus supplement and accompanying prospectus relating to the offering, when available, may be obtained by contacting Aegis Capital Corp., 810 7th Avenue, 18th Floor, New York, NY 10019, (212) 813-1010 or by accessing the SEC's website, [www.sec.gov](http://www.sec.gov).

This press release does not and shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. Any offer, if at all, will be made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement.

### About OpGen

OpGen, Inc. is harnessing the power of informatics and genomic analysis to provide complete solutions for patient, hospital, and network-wide infection prevention and treatment. For more information, please visit [www.opgen.com](http://www.opgen.com).

OpGen, Acuitas, Acuitas Lighthouse, and QuickFISH are registered trademarks of OpGen, Inc.

The Acuitas AMR Gene Panel u5.47 (RUO) and the Acuitas Lighthouse Software (RUO) are intended for Research Use Only and are not for use in diagnostic procedures. The Acuitas Lighthouse Software is not distributed commercially for antibiotic resistance prediction and is not for use in diagnostic procedures.

### Forward-Looking Statements

This press release includes statements relating to the expected proceeds from the Company's public offering, the closing of the offering and the use of the net proceeds to further the development and commercialization of the Company's products and services. These statements and other statements regarding OpGen's future plans and goals constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include, but are not limited to, our ability to successfully, timely and cost-effectively develop, seek and obtain regulatory clearance for and commercialize our product and services offerings, our ability to successfully complete the pilot portion of the NY State project, the rate of adoption of our products and services by hospitals and other healthcare providers, the effect on our business of existing and new regulatory requirements, and other economic and competitive factors. For a discussion of the most significant risks and uncertainties associated with OpGen's business, please review our filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

### OpGen Contact:

Michael Farmer  
Vice President, Marketing  
(240) 813-1284  
[mfarmer@opgen.com](mailto:mfarmer@opgen.com)  
[InvestorRelations@opgen.com](mailto:InvestorRelations@opgen.com)

### Investor Contacts:

LHA Investor Relations  
Kim Sutton Golodetz  
(212) 838-3777  
[kgolodetz@lhai.com](mailto:kgolodetz@lhai.com)  
or  
Bruce Voss  
(310) 691-7100

[bvoss@lhai.com](mailto:bvoss@lhai.com)



Source: OpGen, Inc.